Chordomas are rare bone tumors and treatment is commonly based on a combination of surgery and radiotherapy. There is no standard chemotherapy treatment for chordoma. The aim of this study was to determine the expression of cyclin-dependent kinase 4 (CDK4) in chordoma and its therapeutic implications. We evaluated CDK4 expression both in chordoma cell lines and in chordoma tissues. Also, we investigated the functional roles of CDK4 in chordoma cell growth and proliferation. Furthermore, the therapeutic implications of targeting CDK4 in chordoma were evaluated. We found CDK4 highly expressed in chordoma cell lines and in a majority (97.7%) of chordoma tissues. Higher CDK4 expression correlated with metastasis and recurrence of chordoma. Treatment of chordoma cells using CDK4 inhibitor palbociclib could efficiently inhibit chordoma cells growth and proliferation. These data demonstrate that targeting CDK4 may be useful as a novel strategy in the treatment of chordoma. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1581-1589, 2018.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jor.23819 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).
BMC Cancer
December 2024
ISTCT UMR 6030-CNRS, Université de Caen-Normandie, Caen, 14000, France.
Background: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems.
View Article and Find Full Text PDFDiagnostic Utility of Squash Smear Cytology in Chordoma: A Tertiary Care Center Experience.
J Cytol
November 2024
Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Background And Aims: Chordomas are rare notochordal tumors. They are suitable candidates for squash smear cytology (SSC) owing to their gelatinous consistency and destructive nature. SSC is an important tool for making a quick intra-operative preliminary diagnosis and taking real-time surgical and further management decisions.
View Article and Find Full Text PDFLetter to the Editor Regarding "Extent of Surgical Resection as a Predictor of Tumor Progression in Skull Base Chordomas: A Multicenter Volumetric Analysis" by Carlos et al.
World Neurosurg
December 2024
National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
A rare case of primary chordoma of the nasopharynx mimicking nasopharyngeal carcinoma: A case report.
Int J Surg Case Rep
December 2024
Department of Internal medicine, Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia.
Introduction And Importance: Chordoma is an uncommon malignant tumor that originates from the remnants of the primitive notochord in the embryo. They account for 1 % of intracranial tumors and 4 % of primary bone tumors. It is a locally aggressive tumor with a low risk of metastasis.
View Article and Find Full Text PDFIntraoperative Molecular Imaging With Pafolacianine: Histologic Characteristics of Identified Nodules.
Clin Lung Cancer
November 2024
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH. Electronic address:
Background: With increased early detection efforts, surgery for early-stage lung cancer is expected to rise. Pafolacianine is the first FDA approved targeted optical imaging agent indicated as an adjunct for intraoperative identification of malignant and nonmalignant pulmonary lesions in adult patients with known or suspected cancer in the lung.
Methods: This is a retrospective review of the malignant and nonmalignant lesions identified by pafolacianine with intraoperative molecular imaging (IMI) in the multi-center Phase 2 and Phase 3 ELUCIDATE clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!